Collectively, SUEHP alleviates PD-associated pain and neurodegeneration through CB1 and PPARγ pathways, suggesting its potential as a safe, noninvasive complementary therapy for PD symptom management. This evidence concerns the gene CNR1 and Parkinson disease.